Challenges of designing trials for the primary prevention of stroke

Stroke

Volumn 40, Issue 3 SUPPL. 1, 2009, Pages

  Gorelick, Philip B ^a,b  

^a UNIVERSITY OF ILLINOIS   (United States)

^b Alexian Brothers Hospital Network   (United States)

Author keywords

Clinical trials; Primary prevention; Stroke

Indexed keywords

ACETYLSALICYLIC ACID;

ADULT; AGED; AGING; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CEREBROVASCULAR DISEASE; CLINICAL RESEARCH; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETES MELLITUS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OUTCOMES RESEARCH; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; RISK FACTOR; RISK REDUCTION; STROKE;

AGED; AGED, 80 AND OVER; ASPIRIN; CARDIOVASCULAR DISEASES; HUMANS; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE; PLATELET AGGREGATION INHIBITORS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK FACTORS; STROKE; UNITED STATES;

EID: 62949107148     PISSN: 00392499     EISSN: None     Source Type: Journal    
DOI: 10.1161/STROKEAHA.108.526947     Document Type: Conference Paper

References (18)

1. Gorelick PB. The future of stroke prevention by risk factor modification. In: Fisher M, ed. Handbook of Clinical Neurology: Stroke. In press.
2. Strong K, Mathers C, Bonita R. Preventing stroke: saving lives around the world. Lancet Neurol. 2007;6:182-187.
3. Rosamond W, Flegal K, Furie K, Go A, Greenlund K, Haase N, Halipern SN, Ho M, Howard V, Kissela B, Kittner S, Lloyd-Jones D, McDermott M, Meigs J, Moy C, Nichol G, O'Donnell C, Roger V, Sorlie P, Steinberger J, Thorn T, Wilson M, Hong Y; American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics - 2008 update. A report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation. 2008;117:e25-e146.
4. Radziszewska B, Hart RG, Wolf PA, D'Agostino RB Sr, Cutler JA. Clinical research in primary stroke prevention: needs, opportunities and challenges. Neuroepidemiology. 2005;25:91-104.
5. ARRIVE trial registration. Available at: http://clinicaltrials.gov/ct2/ show/NCT00501059?term=aspirin+bayer&rank=1. Accessed May 24, 2008.
6. Peto R, Gray R, Collins A, Wheatley K, Hennekens C, Jamrozik K, Warlow C, Hafner B, Thompson E, Norton S, et al. Randomized trial of prophylactic daily aspirin in British male doctors. BMJ. 1988;296: 313-316.
7. Steering Committee of the Physicians' Health Study Research Group. Final report on the aspirin component of the ongoing Physicians' Health Study. N Engl J Med. 1989;321:129-135.
8. The Medical Research Council's General Practice Research Framework. Thrombosis Prevention Trial: randomized trial of low intensity oral anticoagulation with warfarin and low-dose aspirin in the primary prevention of ischemic heart disease in men at increased risk. Lancet. 1998;351: 233-241.
9. Hansson L, Zanchetti A, Carruthers SG, Dahlöf B, Elmfeldt D, Julius S, Ménard J, Rahn KH, Wedel H, Westerling S. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal treatment (HOT) randomized trial. Lancet. 1998;351:1755-1762.
10. de Gaetano G, Collaborative Group of the Primary Prevention Project. Low-dose aspirin and vitamin E in people at cardiovascular risk: a randomized trial in general practice. Lancet. 2001;357:89-95.
11. Ridker PM, Cook NR, Lee IM, Gordon D, Gaziano JM, Manson JE, Hennekens CH, Buring JE. A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women. N Engl J Med. 2005;352:1293-1304.
12. International Task Force for Prevention of Coronary Heart Disease. Available at: http://chdrisk.uni-muenster.de/caculator.php. Accessed May 24, 2008.
13. National Cholesterol Education Program (NCEP). Available at: http://hp2010.nhlbihin.net/atpiii/calculator.asp?usertype=prof. Accessed May 24, 2008.
14. Conroy RM, Pyorala K, Fitzgerald AP, Sans S, Menotti A, De Backer D, De Bacquer D, Ducimetière P, Jousilahti P, Keil U, Njølstad I, Oganov RG, Thomsen T, Tunstall-Pedoe H, Tverdal A, Wedel H, Whincup P, Wilhelmsen L, Graham IM; SCORE Project Group. Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project. Eur Heart J. 2003;24:987-1003.
15. Robinson JG, Bakris G, Torner J, Stone NJ, Wallace R. Is it time for a primary prevention trial in the elderly? Stroke. 2007;38:441-450.
16. Gorelick PB. Uncertainty of management of blood pressure and lipids in the elderly: time for a primary prevention trial. Stroke. 2007;38:212-213.
17. Rothwell PM, Coull AJ, Silver LE, Farihead JF, Giles MF, Lovecock CE, Redgrave JN, Bull LM, Welch SJ, Cuthbertson FC, Binney LE, Gutnikov SA, Anslow P, Banning AP, Mant D, Mehta Z; Oxford Vascular Study. Population-based study of event rate, incidence, case fatality and mortality for all acute vascular events in all arterial territories (Oxford Vascular Study). Lancet. 2005;366:1773-1783.
18. Beckett NS, Peters R, Fletcher AE, Staessen JA, Liu L, Dimitrascu D, Stoyanovsky V, Antikainen RL, Nikitin Y, Anderson C, Belhani A, Forette F, Rajkumar C, Thijs L, Banya W, Bulpitt CJ; HYVET Study Group. Treatment of hypertension in patients 80 years of age or older. N Engl J Med. 2008;358:1887-1898.